The AQ Shunt™

By Vickie Stubbs

Next Generation Glaucoma Drainage Device Reduces Patient Risk and Healthcare Costs

Boulder, CO – Locally owned Boulder iQ is proud to announce our partnership with AQ BioMed in the development of the AQ Shunt. AQ Shunt’s unique and patented design virtually eliminates complications of other glaucoma devices.

The AQ Shunt’s unique design and disruptive technology will set a new standard of care with improvements to patient safety by reducing complications and health care costs.

AQ BioMed is commercializing the AQ Shunt to address the number two cause of blindness in the world, glaucoma. There are over 60 million people suffering from glaucoma globally and over 2.2 million people in the U.S. alone. Glaucoma causes blindness in 25,000 U.S. patients each year.

We are seeking a second round of funding and are featured on Red Crow Supernova new crowdsourcing feedback and funding opportunity site.
The team is headed up by Jim Kasic, President, and CEO, who is a serial entrepreneur with over 25 years’ experience in Class I, II, and III medical device industry. His range of experience spans large multi-national organizations to start-ups with both national and international scope and holds 40 U.S. and international patents and dozens of scientific publications. He has a Bachelor of Science degree in physics, Master of Science degree in chemical/biological engineering, and Master of Business Administration.

Contact
Boulder iQ
Vickie Stubbs, Business Development
2840 Wilderness Place, Suite D
Boulder, CO 80304
Office: (303) 531-1238 Ext. 702
Vickie.stubbs@boulderiq.com